Skip to main content
Log in

Das Zusammenwirken von Rhodiola rosea (Eisenwurz) und Antidepressiva

The interaction of Rhodiola rosea and antidepressants. A case report

  • fallbericht
  • Published:
neuropsychiatrie Aims and scope Submit manuscript

An Erratum to this article was published on 27 April 2023

This article has been updated

Zusammenfassung

Anliegen

Rhodiola rosea (Eisenwurz) ist eine Hochgebirgspflanze aus den arktischen Gebieten Europas und Asiens, die als einzige aller Rhodiola-Arten spezifische Wirkstoffe, nämlich die Phenylpropanoide, beinhaltet. Rhodiola rosea wirkt beruhigend, antidepressiv, antriebssteigernd und stressmodulierend und moduliert Dopamin und Serotonin im Gehirn; Extrakte aus dem Rhizom können in Kombination mit anderen Arzneimitteln Nebenwirkungen mit sich bringen.

Methode

Anhand eines Fallberichts soll dieser Zusammenhang beschrieben werden.

Ergebnisse

Wir berichten über eine 68-jährige Patientin mit rezidivierender mittelgradiger Depression mit somatischem Syndrom (ICD-10 F33.11), die unter der Selbstmedikation von Eisenwurz bei gleichzeitiger Einnahme von Paroxetin u. a. vegetative Syndrome, Unruhe-Gefühl und leichtes Zittern entwickelt hatte.

Schlussfolgerungen

Rhodiola rosea kann mit anderen Arzneimitteln pharmakokinetische sowie -dynamische Interaktionsphänomene auslösen. Das Auftreten der Symptome der Patientin lässt sich am ehesten als serotonerges Syndrom erklären. Aufgrund der weitverbreiteten Verschreibung der Pflanze sollte an Wechselwirkungen und Risikoprofile gedacht werden.

Summary

Objective

Rhodiola rosea (Russian Rhodiola/Golden Root) is a high mountain plant from the arctic regions of Europe and Asia which has the active substance phenylpropanoide. It has sedative, anti-depressive, drive-enhancing and stress-modulated properties stimulating the distribution of dopamine and serotonin; in combination with other drugs, an increase of side effects and risk profile has to be expected.

Methods

A case report is presented in order to illustrate the interaction between Rhodiola rosea and antidepressants.

Results

We report the case of a 68-year-old female patient with recurrent moderate depressive disorder with somatic syndrome (ICD-10 F33.11) who developed vegetative syndrome, restlessness feeling and trembling since she began to ingest Rhodiola rosea in addition to paroxetine.

Conclusions

Prescribing Rhodiola rosea with paroxetine, pharmacokinetic and -dynamic interactions have to be assumed. The symptoms of the patient can be interpreted as a serotonergic syndrome. Because of its different effects, the plant is widely used. An increase of clinical relevant risks should be considered in the add-on treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Change history

Literatur

  1. Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmstroem C, Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry. 2007;61(5):343–8.

    Article  CAS  PubMed  Google Scholar 

  2. Lucki I. The forced swimming test as a model for core and components behavioral effects of antidepressant drugs. Behav Pharmacol. 1997;8:523–32.

    Article  CAS  PubMed  Google Scholar 

  3. Mattioli L, Perfumi M. A Rhodiola rosea extract reduced stress and CRF-induced anorexia in rats. In 53rd Annual Congress of the Society of Medicinal Plant Reserarch (GA). Florence 2005; August 21–25, book of abstracts; 173.

  4. Lishmanov IB, Trifonova ZHV, Tsibin AN, Maslova LV, Dementeva LA. Plasma beta-endorphin and stress hormones in stress and adaptation. Bull Exp Biol Med. 1987;103:422–4.

    Article  CAS  Google Scholar 

  5. Hellum BH, Tosse A, Hoybakk K, Thomsen M., Rohloff J, Nilsen GO. Potent in vitro inhibition of CYP3A4 and P-glycoprotein by Rhodiola rosea. Planta Med. 2010;76(4):331–8.

    Article  CAS  PubMed  Google Scholar 

  6. Van Diermen D, Marston A, Bravo J, Reist M, Carrupt PA, Hostettmann KJ. Monoamine oxidase inhibition by Rhodiola rosea L. roots. J Ethnopharmacol. 2009;122(2):397–401.

    Article  PubMed  Google Scholar 

  7. McGovern E, McDonnell TJ. Herbal medicine-sets the heart racing. Ir Med Journal. 2010;103(7):219.

    CAS  Google Scholar 

  8. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44(6):195–235.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ignazio Maniscalco.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maniscalco, I., Toffol, E., Giupponi, G. et al. Das Zusammenwirken von Rhodiola rosea (Eisenwurz) und Antidepressiva. Neuropsychiatr 29, 36–38 (2015). https://doi.org/10.1007/s40211-014-0124-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40211-014-0124-8

Schlüsselwörter

Keywords

Navigation